Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 174

1.

Robotic radical cystectomy - revision and resection: An evolution in operative technique and platforms.

Goonewardene SS, Persad R, Gillatt D.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12578. No abstract available.

PMID:
28657209
2.

The role of enhanced recovery in open or robotic cystectomy.

Goonewardene SS, Persad R, Gillatt D.

Urol Oncol. 2017 Jun;35(6):447. doi: 10.1016/j.urolonc.2016.05.004. Epub 2017 Apr 29. No abstract available.

PMID:
28460800
3.

Who is at risk of death from nephrectomy? An analysis of thirty-day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit.

Fernando A, Fowler S, Van Hemelrijck M, O'Brien T; British Association of Urological Surgeons (BAUS).

BJU Int. 2017 Apr 24. doi: 10.1111/bju.13842. [Epub ahead of print]

PMID:
28440053
4.

Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.

Chang L, Ni J, Beretov J, Wasinger VC, Hao J, Bucci J, Malouf D, Gillatt D, Graham PH, Li Y.

Sci Rep. 2017 Feb 22;7:41834. doi: 10.1038/srep41834.

5.

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Biernacka KM, Persad RA, Bahl A, Gillatt D, Holly JM, Perks CM.

Endocr Relat Cancer. 2017 Jan;24(1):17-30. Epub 2016 Oct 17.

6.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

7.

Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.

Hao J, Graham P, Chang L, Ni J, Wasinger V, Beretov J, Deng J, Duan W, Bucci J, Malouf D, Gillatt D, Li Y.

Oncotarget. 2016 Nov 8;7(45):74269-74285. doi: 10.18632/oncotarget.12368.

8.

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*.

N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14.

9.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.

10.

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA, Staffurth JN; ProtecT Study Group.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e92-e100. doi: 10.1016/j.clon.2016.05.011. Epub 2016 Jul 12.

PMID:
27425582
11.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

12.

Erectile function post robotic radical prostatectomy: technical tips to improve outcomes?

Goonewardene SS, Persad R, Gillatt D.

J Robot Surg. 2016 Sep;10(3):267-9. doi: 10.1007/s11701-016-0578-8. Epub 2016 Jun 7. Review.

PMID:
27272758
13.

Robotic cystectomy and intracorporeal stoma formation: Robotic management of ureteric strictures.

Goonewardene SS, Persad R, Gillatt D.

Urol Oncol. 2016 Aug;34(8):375-6. doi: 10.1016/j.urolonc.2016.05.003. Epub 2016 Jun 2. No abstract available.

PMID:
27264168
14.

Robotic radical cystectomy and enhanced recovery: a new pathway.

Goonewardene SS, Persad R, Gillatt D.

World J Urol. 2016 Nov;34(11):1599-1600. Epub 2016 Mar 24. No abstract available.

PMID:
27010207
15.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

16.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial.

Hackshaw-McGeagh L, Lane JA, Persad R, Gillatt D, Holly JM, Koupparis A, Rowe E, Johnston L, Cloete J, Shiridzinomwa C, Abrams P, Penfold CM, Bahl A, Oxley J, Perks CM, Martin R.

Trials. 2016 Mar 7;17(1):123. doi: 10.1186/s13063-016-1248-x.

17.

Robotic radical cystectomy: intracorporeal versus extracorporeal versus orthotopic neobladder-Which is better?

Goonewardene SS, Persad R, Gillatt D.

World J Urol. 2016 Oct;34(10):1501-2. doi: 10.1007/s00345-016-1783-9. Epub 2016 Feb 12. No abstract available.

PMID:
26873597
18.

Cancer stem cells and signaling pathways in radioresistance.

Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, Malouf D, Gillatt D, Li Y.

Oncotarget. 2016 Mar 8;7(10):11002-17. doi: 10.18632/oncotarget.6760. Review.

19.

Penile rehabilitation for robotic radical prostatectomy: a new game.

Goonewardene SS, Persad R, Gillatt D.

J Robot Surg. 2016 Dec;10(4):379-380. Epub 2015 Dec 24. No abstract available.

PMID:
26705112
20.

Nephron-sparing surgery across a nation - outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit.

Fernando A, Fowler S, O'Brien T; British Association of Urological Surgeons (BAUS).

BJU Int. 2016 Jun;117(6):874-82. doi: 10.1111/bju.13353. Epub 2015 Nov 18.

Supplemental Content

Loading ...
Support Center